Welcome to our dedicated page for Adaptimmune Therapeutics Plc news (Ticker: ADAP), a resource for investors and traders seeking the latest updates and insights on Adaptimmune Therapeutics Plc stock.
Adaptimmune Therapeutics plc (ADAP) generates a steady flow of news centered on its work in engineered T cell receptor (TCR) cell therapies for solid tumor cancers. Company announcements cover clinical progress, regulatory milestones, commercial activity, strategic transactions and corporate restructuring, providing context for how its business and ADAP stock have evolved over time.
Recent news highlights include the launch and commercial metrics for TECELRA, an engineered T-cell therapy that Adaptimmune describes as the first such therapy approved in the U.S. for a solid tumor cancer, as well as pivotal trial results and regulatory plans for lete-cel in synovial sarcoma and myxoid/round cell liposarcoma. Releases detail Authorized Treatment Center activation, patient aphereses, invoiced doses and manufacturing performance, giving readers insight into how the company has executed on its sarcoma franchise.
Investors following ADAP news will also find coverage of Adaptimmune’s definitive agreement and subsequent transaction with US WorldMeds, under which the company sold the assets and rights related to Tecelra, lete-cel, afami-cel and uza-cel. These stories explain the upfront and potential milestone payments, transfer of employees, and associated transition and license agreements. Additional updates describe the repayment of debt to Hercules Capital and the company’s efforts to maximize value from remaining preclinical assets such as PRAME- and CD70-directed programs.
Other Adaptimmune news items focus on Nasdaq listing compliance notices, the Board’s decision to voluntarily delist the company’s ADSs from The Nasdaq Capital Market and pursue deregistration, and the expectation that trading may move to an over-the-counter market. Executive leadership changes, headcount reductions, cost-saving initiatives and going concern disclosures are also covered. For readers tracking ADAP, this news page brings together financial results, regulatory filings, scientific conference presentations and strategic updates in one place.
Adaptimmune Therapeutics has announced the treatment of its first patient with TECELRA® at Moffitt Cancer Center. This marks a significant milestone as TECELRA becomes the first FDA-approved engineered cell therapy for solid tumor cancer in the U.S., specifically for synovial sarcoma.
The FDA granted accelerated approval in August 2024 for TECELRA to treat adults with unresectable or metastatic synovial sarcoma who meet specific criteria, including prior chemotherapy and certain genetic markers. The treatment network includes several Authorized Treatment Centers across the US, with plans to expand to approximately 30 centers by the end of 2025, covering 80% of patients in sarcoma centers of excellence.
Adaptimmune Therapeutics (NASDAQ: ADAP) reports Q3 2024 updates with Total Liquidity of $186.1 million. The company announces a strategic restructuring with a planned 33% headcount reduction in Q1 2025, targeting approximately $300 million in cost savings over four years. The Tecelra® launch is progressing with 9 Authorized Treatment Centers, and the first patient has been apheresed. The company reports a 42% overall response rate in the lete-cel IGNYTE-ESO pivotal trial for synovial sarcoma and MRCLS. Q3 revenue was $40.9 million, and the company aims to achieve operating breakeven during 2027.
Adaptimmune Therapeutics (NASDAQ: ADAP) announced positive results from its pivotal Phase 2 IGNYTE-ESO trial of lete-cel in patients with synovial sarcoma or myxoid/round cell liposarcoma (MRCLS). The trial achieved a 42% response rate (27/64 patients), including six complete responses and 21 partial responses. The median duration of response was 18.3 months for synovial sarcoma and 12.2 months for MRCLS. Based on these results, the company plans to initiate a rolling Biologics License Application submission by end of 2025.
Adaptimmune Therapeutics (NASDAQ: ADAP) has announced its participation in three major scientific conferences: SITC (November 6-10, Houston), CTOS (November 13-16, San Diego), and ASH (December 7-10, San Diego). The company will present research on cell therapies for solid tumors, particularly focusing on synovial sarcoma treatments.
Key presentations include data on afami-cel's anti-tumor activity, the IGNYTE-ESO trial results, and decentralized manufacturing processes. A notable virtual event is scheduled for November 18, featuring Dr. Sandra D'Angelo from Memorial Sloan Kettering Cancer Center, discussing the IGNYTE-ESO dataset and engineered cell therapies' impact on sarcoma treatment.
Adaptimmune Therapeutics (NASDAQ: ADAP), a cell therapy company focused on solid tumor cancers, will announce its Q3 2024 financial results and business updates after US markets close on November 13, 2024. The company will host a live webcast at 4:30 p.m. EDT (9:30 p.m. GMT). The press release will be available on Adaptimmune's corporate website, and investors can access the webcast through a provided link. Call-in options are available for US/Canada (+1-844-763-8274) and International (+1-647-484-8814) participants.
Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company focused on redefining solid tumor cancer treatment with cell therapy, has announced its participation in two major investment bank conferences this September:
1. Wells Fargo Healthcare Conference in Boston, MA on September 4, 2024, at 4:30 PM EDT.
2. H.C. Wainwright 26th Annual Global Investment Conference in NYC, NY on September 9, 2024, at 9:50 AM EDT.
Both events will feature fireside chats and will be webcast live on Adaptimmune's website. Replays will be available for a time after the events.
Adaptimmune Therapeutics plc (Nasdaq: ADAP) reported Q2 2024 financial results and business updates. Key highlights include:
1. U.S. FDA approval of Tecelra® (afami-cel), the first engineered cell therapy for solid tumors.
2. Total Liquidity of $214.8 million at the end of Q2.
3. Revenue increased to $128.2 million for Q2 2024, compared to $5.1 million in Q2 2023.
4. Net profit of $69.5 million for Q2 2024, compared to a loss of $21.3 million in Q2 2023.
5. Plans to initiate rolling BLA submission for lete-cel in 2025 and commercial launch in 2026.
6. Projected peak U.S. sales of $400 million for the sarcoma franchise.
Adaptimmune Therapeutics plc (Nasdaq: ADAP), a company focused on redefining solid tumor cancer treatment with cell therapy, has announced it will release its Q2 2024 financial results and business updates on Monday, August 12, 2024, before US markets open. The company will host a live webcast at 8:00 a.m. EDT (1:00 p.m. BST) on the same day to discuss the results.
Investors can access the press release on Adaptimmune's corporate website, and join the webcast at https://www.gowebcasting.com/13404. For those preferring to call in, the numbers are +1-844-763-8274 (US/Canada) or +1-647-484-8814 (International). Participants are advised to dial in 10 minutes before the scheduled start time.
Adaptimmune Therapeutics (NASDAQ: ADAP) has received FDA accelerated approval for TECELRA® (afamitresgene autoleucel), the first engineered cell therapy for a solid tumor approved in the U.S. TECELRA is approved for treating adults with advanced MAGE-A4+ synovial sarcoma who have specific HLA types and have received prior chemotherapy.
Key points:
- First new treatment for synovial sarcoma in over a decade
- 43% overall response rate in the SPEARHEAD-1 trial
- Approval based on response rate and duration; confirmatory trial required
- Adaptimmune plans to onboard ~30 treatment centers within two years
- Companion diagnostics for HLA type and MAGE-A4 expression approved
TECELRA can cause serious side effects, including cytokine release syndrome and neurotoxicity. Adaptimmune will hold a webcast on August 2 to provide additional details.
Adaptimmune Therapeutics (NASDAQ: ADAP) presented interim analysis data from its pivotal IGNYTE-ESO trial at ASCO. The study focuses on lete-cel, an engineered cell therapy targeting NY-ESO-1, in synovial sarcoma (SyS) and myxoid/round cell liposarcoma (MRCLS). The trial achieved a 40% overall response rate (ORR) across both cancer types and a median duration of response (mDOR) of approximately 11 months. These findings reinforce the potential of lete-cel to address unmet medical needs in these sarcoma indications. Full results are expected in late 2024, with a Biologics License Application (BLA) submission planned for 2025. Adaptimmune aims to commercialize afami-cel later this year and lete-cel in 2026.